Vesalius Announces Multi-Target Strategic Alliance with GSK to …
2 days ago · Vesalius' platform uses large-scale human genetics, genomics, stem cell studies and artificial intelligence to uncover causal biology and identify optimal intervention points for new therapies.
GSK pays Flagship biotech $80M for preclinical neuro pact
2 days ago · GSK inks Parkinson's pact with Flagship's Vesalius for $570M-plus biobucks. GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
GSK Steps Up Parkinson’s Focus With US Biotech Deal
2 days ago · Listen. 1:49. GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug development for Parkinson’s disease. GSK will pay $80 ...
Vesalius Announces Multi-Target Strategic Alliance with GSK
2 days ago · Vesalius Will Apply its Proprietary Platform to Identify Novel Intervention Points that GSK may Advance for the Treatment of Patients with Parkinson’s Disease. GSK has Licensed a Preclinical Small Molecule Inhibitor Program. ... BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools ...
GSK partners with Flagship startup to hunt for Parkinson’s drugs
2 days ago · Permission granted by Flagship Pioneering. Flagship Pioneering startup Vesalius Therapeutics has signed a deal with GSK, the companies announced Tuesday, for the British pharma to use its technology to find medicines for neurodegenerative disorders. Under the terms of the deal, GSK will hand Vesalius $80 million in upfront and equity payments.
Vesalius Announces Multi-Target Strategic… | Flagship Pioneering
2 days ago · Cambridge, Mass., November 12, 2024 – Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, today announced a multi-target strategic alliance with GSK to discover and develop novel treatments for Parkinson’s disease, and another undisclosed neurodegenerative indication.
Vesalius-GSK $650M pact: Targeting Parkinson’s root causes
1 day ago · More than two years since emerging from stealth, Vesalius Therapeutics Inc. signed its first major pharma deal with GSK plc. Worth up to $650 million and possibly more if an option is exercised, the multitarget alliance aims to discover and develop novel treatments for Parkinson’s disease and another neurodegenerative indication. Nearly $3.8 ...
GSK inks multi-target alliance with Versalius
1 day ago · 13 November 2024. Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK (LSE: GSK) to discover and develop novel treatments for Parkinson's disease, and another undisclosed neurodegenerative indication. The deal marks GSK's second major foray into neurodegenerative diseases in recent ...
Vesalius and GSK Form Multi-Target Strategic Alliance to Develop ...
2 days ago · The Life Sciences team advised Vesalius Therapeutics in its multi-target strategic alliance with GSK to discover and develop novel treatments for Parkinson's disease, and another undisclosed neurodegenerative indication. Vesalius will leverage its platform to identify novel intervention points in Parkinson's disease and one additional indication in neurodegeneration, and GSK will have the ...
Flagship unveils Vesalius with $75M to bankroll ambitious target …
Mar 2, 2022 · Now, 30-plus years later, the two have come together to co-found Flagship's Vesalius Therapeutics in a $75 million attempt to solve the problem. The Cambridge, Massachusetts biotech, emerged ...